

**Date:** 12<sup>th</sup> November, 2024

To,  
**National Stock Exchange of India Limited**  
“Exchange Plaza”, C-1, Block G,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

Dear Sir / Madam,

**Sub: Submission of Standalone and Consolidated Unaudited Financial Results for the Half Year ended on 30<sup>th</sup> September, 2024 along with Limited Review Report**

**Ref: Security Id: WALPAR / Series: SM**

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Standalone and Consolidated Unaudited Financial Results for the Half Year ended on 30<sup>th</sup> September, 2024 along with Limited Review Report.

Kindly take the same on your record and oblige us.

**For, Walpar Nutritions Limited**

**Kalpesh Ladhawala**  
**Managing Director**  
**DIN: 02849232**

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Unaudited Financial Results for the Half Year ended on September 30, 2024 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

(Amount in Lakhs)

	Particulars	Half Year ended on 30/09/2024	Half Year ended on 31/03/2024	Half Year ended on 30/09/2023	Year to date figures for the year ended 30/09/2024	Year to date figures for the year ended 30/09/2023	Year to date figures for the year ended 31/03/2024
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	<b>INCOME FROM OPERATIONS</b>						
I	Revenue from Operations	2491.54	2582.68	2548.73	2491.54	2548.73	5131.41
II	Other Income	3.43	11.16	1.80	3.43	1.80	12.96
III	<b>Total Revenue (I+II)</b>	<b>2494.97</b>	<b>2593.84</b>	<b>2550.53</b>	<b>2494.97</b>	<b>2550.53</b>	<b>5144.38</b>
IV	<b>EXPENSES</b>						
	Cost of Material Consumed	2195.38	2142.87	2351.37	2195.38	2351.37	4494.24
	Purchase of Stock in Trade		0.00	0.00	0.00	0.00	0.00
	Change in inventories of Finished Goods, Work-in-progress & Stock in Trade	-50.96	140.68	(43.68)	-50.96	-43.68	97.00
	Employee Benefit Expenses	94.47	72.64	96.94	94.47	96.94	169.58
	Finance Cost	5.07	10.42	10.16	5.07	10.16	20.58
	Depreciation & Amortization Expense	17.58	11.03	9.57	17.58	9.57	20.60
	Other Expenses	95.54	103.20	91.25	95.54	91.25	194.45
	<b>Total expenses (IV)</b>	<b>2357.09</b>	<b>2480.84</b>	<b>2515.61</b>	<b>2357.09</b>	<b>2515.61</b>	<b>4996.45</b>
V	<b>Profit before Exceptional &amp; Extraordinary Items and tax (III-IV)</b>	<b>137.89</b>	<b>113.01</b>	<b>34.93</b>	<b>137.89</b>	<b>34.93</b>	<b>147.93</b>
VI	Exceptional Items		-	-	-	-	-
VII	<b>Profit before Extraordinary Items and tax (V-VI)</b>	<b>137.89</b>	<b>113.01</b>	<b>34.93</b>	<b>137.89</b>	<b>34.93</b>	<b>147.93</b>
VIII	Prior Period Items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit before tax (VII-VIII)</b>	<b>137.89</b>	<b>113.01</b>	<b>34.93</b>	<b>137.89</b>	<b>34.93</b>	<b>147.93</b>
X	<b>Tax Expenses</b>						
	1 Current Tax	33.60	25.34	7.35	33.60	7.35	32.69
	2 Deferred Tax	-7.29	3.38	1.04	-7.29	1.04	4.42
	3 Tax Related to Earlier Years	0.00	(0.31)	-	0.00	-	(0.31)
	<b>Total Tax Expenses (X)</b>	<b>26.31</b>	<b>28.41</b>	<b>8.39</b>	<b>26.31</b>	<b>8.39</b>	<b>36.80</b>
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>111.58</b>	<b>84.60</b>	<b>26.54</b>	<b>111.58</b>	<b>26.54</b>	<b>111.13</b>
XII	Profit/(Loss) from discontinuing operation	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	<b>Profit/(Loss) from discontinuing operation after tax (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit/(Loss) for the Period (XI+XIV)</b>	<b>111.58</b>	<b>84.60</b>	<b>26.54</b>	<b>111.58</b>	<b>26.54</b>	<b>111.13</b>
XVI	<b>Paid up Equity Share Capital</b>	<b>939.04</b>	<b>469.52</b>	<b>469.52</b>	<b>939.04</b>	<b>469.52</b>	<b>469.52</b>
XVII	<b>Reserves &amp; Surplus</b>	<b>505.91</b>	<b>863.85</b>	<b>779.77</b>	<b>505.91</b>	<b>779.77</b>	<b>863.85</b>
XVIII	Earnings per equity share						
	(1) Basic	1.19	0.90	0.28	1.19	0.28	1.18
	(2) Diluted	1.19	0.90	0.28	1.19	0.28	1.18

Notes:-

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 12, 2024
- The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opinion on these Results.
- There are no investor complaints received/pending as on September 30, 2024
- Previous year/s/ period figures have been regrouped/ reclassified/ restated, wherever necessary to conform to classification of current year/period.
- AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

For Walpar Nutritions Limited

Kalpesh P Ladhawala  
Managing Director  
DIN : 02849232

Place : Gandhinagar  
Date : November 12, 2024

**WALPAR NUTRITIONS LIMITED**

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Assets & Liabilities as on September 30, 2024

(Amount in Lakhs)

Particulars		As on 30th September 2024	As on 31st March 2024
		Unaudited	Audited
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>1 Shareholders' funds</b>		
	Share capital	939.04	469.52
	Reserves and surplus	505.91	863.85
		<b>1,444.95</b>	<b>1,333.37</b>
	<b>2 Non-current liabilities</b>		
	Long Term Borrowings	-	-
	Deferred Tax Liabilities (Net)	-	-
	Other Long Term Liabilities	-	-
	Long Term Provision	-	-
		-	-
	<b>3 Current liabilities</b>		
	Short Term Borrowings	106.61	31.53
	Trade Payables		
	(i) Total outstanding dues of micro enterprises and small enterprises		-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,413.49	843.96
	Other Current Liabilities	40.19	107.85
	Short Term Provisions	33.60	32.69
		<b>1,593.89</b>	<b>1,016.04</b>
	<b>TOTAL</b>	<b>3,038.83</b>	<b>2,349.41</b>
<b>II.</b>	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	<b>Property Plant &amp; Equipments</b>		
	<b>1 Fixed assets</b>		
	(i) Tangible Assets	176.30	141.24
	(ii) Intangible Assets	6.51	7.23
	(iii) Intangible Assets Under Development	2.30	1.80
	Non Current Investments	469.84	469.84
	Long Term Loans & Advances	-	-
	Deferred Tax Assets	18.90	11.62
	Other Non Current Assets	4.93	5.44
		<b>678.77</b>	<b>637.17</b>
	<b>2 Current assets</b>		
	Current Investments		
	Inventories	551.61	502.92
	Trade Receivables	1,764.79	1,009.11
	Cash and cash equivalents	20.18	44.66
	Short Term Loans & Advances	10.62	130.61
	Other Current Assets	12.87	24.95
		<b>2,360.07</b>	<b>1,712.25</b>
	<b>TOTAL</b>	<b>3,038.83</b>	<b>2,349.41</b>

For Walpar Nutritions Limited

**Kalpesh P Ladhawala**  
**Managing Director**  
**DIN : 02849232**

**Place : Gandhinagar**  
**Date : November 12, 2024**

# WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - [www.walparnutritions.com](http://www.walparnutritions.com); Email : [finance.walpar@hotmail.com](mailto:finance.walpar@hotmail.com)

Standalone Statement of Cash Flows for the year ended on September 30, 2024

(Amount in Lakhs)

Particulars	For the Year Ended on	For the Year Ended on
	30.09.2024	30.09.2023
<b>Cash flows from operating activities</b>		
<b>Profit before taxation</b>	<b>137.89</b>	<b>34.93</b>
<b>Adjustments for:</b>		
Depreciation & Amortization Expenses	17.58	9.57
Investment income	(0.02)	(0.08)
Prior Period Items/Non Cash Items	-	(0.51)
Finance Cost	5.07	10.16
<b>Working capital changes:</b>		
(Increase) / Decrease in Trade Receivables	(755.68)	(635.00)
(Increase) / Decrease in Short Term Loans & Advances	119.99	62.92
(Increase) / Decrease in Other Current Assets	12.08	13.44
(Increase) / Decrease in Inventories	(48.69)	(104.40)
Increase / (Decrease) in Trade Payables	569.53	768.83
Increase / (Decrease) in Other Current Liabilities	(67.66)	(48.10)
Cash generated from operations	<b>(9.92)</b>	<b>111.77</b>
Payment/Adjustmen on Account of Tax Expenses	(32.69)	(11.19)
<b>Net cash from operating activities</b>	<b>(42.61)</b>	<b>100.58</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(52.41)	(0.95)
Investment Income	0.02	0.08
Proceeds/(Payment) for Long Term Loans & Advances	-	119.75
(Increase)/Decrease in Other Non Current Assets	0.51	7.11
Increase in Non Current Investments	0.00	(186.05)
<b>Net cash used in investing activities</b>	<b>(51.87)</b>	<b>(60.06)</b>
<b>Cash flows from financing activities</b>		
Proceeds/ (Repayment) of Short term Borrowings	75.08	-43.90
Proceeds/ (Repayment) of Long term Borrowings	-	-102.63
Proceeds from Share Capital	-	15.40
Proceeds from Securities Premium	-	76.08
Payment of Finance cost	(5.07)	(10.16)
<b>Net cash used in financing activities</b>	<b>70.01</b>	<b>(65.23)</b>
<b>Net increase in cash and cash equivalents</b>	<b>(24.48)</b>	<b>(24.71)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>44.66</b>	<b>37.35</b>
<b>Cash and cash equivalents at end of period</b>	<b>20.18</b>	<b>12.64</b>

0.01

For Walpar Nutritions Limited

Kalpesh P Ladhawala  
Managing Director  
DIN : 02849232

Place : Gandhinagar  
Date : November 12, 2024



# A Y & COMPANY

505, Fifth Floor, ARG Corporate Park

Gopal Bari, Ajmer Road, Jaipur (Raj.)

TEL NO. - +91-9649687300

Email: info@aycompany.co.in

## Limited Review Report on the Half year ended Un-audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended

### Review Report

To

**The Board of Directors  
Walpar Nutritions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Walpar Nutritions Limited** (the 'Company') for the Half Year ended on September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A Y & Company  
Chartered Accountants  
FRN: 020829C**



**Arpit Gupta  
Partner**

**M. No. 421544**

**UDIN – 24421544BKFPPV5942**

**Place: Jaipur**

**Date: 12.11.2024**

**WALPAR NUTRITIONS LIMITED**

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2024 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

(Amount in Lakhs)

	Particulars	Half Year ended on 30/09/2024	Half Year ended on 31/03/2024	Half Year ended on 30/09/2023	Year to Date Figures for Half Year ended on 30/09/2024	Year to Date Figures for Half Year ended on 30/09/2023	Year to date figures for the year ended 31/03/2024
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	<b>INCOME FROM OPERATIONS</b>						
I	Revenue from Operations	3252.56	3138.41	3113.76	3252.56	3113.76	6252.17
II	Other Income	31.01	15.73	6.05	31.01	6.05	21.78
III	<b>Total Revenue (I+II)</b>	<b>3283.57</b>	<b>3154.14</b>	<b>3119.82</b>	<b>3283.57</b>	<b>3119.82</b>	<b>6273.95</b>
	<b>EXPENSES</b>						
	Cost of Material Consumed	2703.97	2413.95	2552.84	2703.97	2552.84	4966.79
	Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Change in inventories of Finished Goods, Work-in-progress & Stock in Trade	-161.29	68.06	(56.46)	-161.29	-56.46	11.60
	Employee Benefit Expenses	226.58	177.49	220.34	226.58	220.34	397.83
	Finance Cost	25.70	34.10	32.79	25.70	32.79	66.89
	Depreciation & Amortization Expense	87.91	88.57	92.41	87.91	92.41	180.98
	Other Expenses	219.91	202.59	197.96	219.91	197.96	400.55
	<b>Total expenses (IV)</b>	<b>3102.78</b>	<b>2984.76</b>	<b>3039.88</b>	<b>3102.78</b>	<b>3039.88</b>	<b>6024.64</b>
V	<b>Profit before Exceptional &amp; Extraordinary Items and tax (III-IV)</b>	<b>180.79</b>	<b>169.39</b>	<b>79.95</b>	<b>180.79</b>	<b>79.95</b>	<b>249.32</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit before Extraordinary Items and tax (V-VI)</b>	<b>180.79</b>	<b>169.39</b>	<b>79.95</b>	<b>180.79</b>	<b>79.95</b>	<b>249.32</b>
VIII	Prior Period Items	0.00	0.00	-	-	-	-
IX	<b>Profit before tax (VII-VIII)</b>	<b>180.79</b>	<b>169.39</b>	<b>79.95</b>	<b>180.79</b>	<b>79.95</b>	<b>249.32</b>
	<b>Tax Expenses</b>						
X	1 Current Tax	46.97	28.79	22.68	46.97	22.68	51.47
	2 Deferred Tax	-7.03	11.33	(7.36)	(7.03)	-7.36	3.97
	2 Tax Related to Earlier Years	0.00	(0.66)	-	-	-	(0.66)
	<b>Total Tax Expenses (X)</b>	<b>39.94</b>	<b>39.47</b>	<b>15.31</b>	<b>39.94</b>	<b>15.31</b>	<b>54.77</b>
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>140.85</b>	<b>129.92</b>	<b>64.64</b>	<b>140.85</b>	<b>64.64</b>	<b>194.55</b>
XII	Profit/(Loss) from discontinuing operation	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	<b>Profit/(Loss) from discontinuing operation after tax (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit/(Loss) for the Period (XI+XIV)</b>	<b>140.85</b>	<b>129.92</b>	<b>64.64</b>	<b>140.85</b>	<b>64.64</b>	<b>194.55</b>
XVI	Profit Attributable to Minority Interest	12.06	11.46	24.89	12.06	24.89	36.35
XVII	Profit Attributable to Owners of Parent	128.79	118.47	39.74	128.79	39.74	158.20
XVIII	<b>Paid up Equity Share Capital</b>	<b>939.04</b>	<b>469.52</b>	<b>469.52</b>	<b>939.04</b>	<b>469.52</b>	<b>469.52</b>
XIX	<b>Reserves &amp; Surplus</b>	<b>616.05</b>	<b>948.76</b>	<b>831.77</b>	<b>616.05</b>	<b>831.77</b>	<b>948.76</b>
XX	Earnings per equity share						
	(1) Basic	1.37	1.26	0.42	1.37	0.42	1.68
	(2) Diluted	1.37	1.26	0.42	1.37	0.42	1.68

**Notes:-**

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 12, 2024.
- The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opinion on these Results.
- There are no investor complaints received/pending as on September 30, 2024.
- Previous year's period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.
- AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

For Walpar Nutritions Limited

Kalpesh P Ladhawala  
Managing Director  
DIN : 02849232

Place : Gandhinagar  
Date : November 12, 2024

**WALPAR NUTRITIONS LIMITED**

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Assets & Liabilities as on September 30, 2024

(Amount in Lakhs)

Particulars		As on 30th September	As on 31st March
		2024	2024
		Unaudited	Audited
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	Share capital	939.04	469.52
	Reserves and surplus	616.05	948.76
		<b>1,555.09</b>	<b>1,418.28</b>
<b>2</b>	<b>Minority Interest</b>	<b>236.21</b>	<b>224.15</b>
<b>3</b>	<b>Non-current liabilities</b>		
	Long Term Borrowings	413.68	407.65
	Deferred Tax Liabilities (Net)	-	-
	Other Long Term Liabilities	-	-
	Long Term Provision	-	-
		<b>413.68</b>	<b>407.65</b>
<b>4</b>	<b>Current liabilities</b>		
	Short Term Borrowings	441.52	422.22
	Trade Payables		
	(i) Total outstanding dues of micro enterprises and small enterprises	-	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	1779.27	994.86
	Other Current Liabilities	117.68	198.11
	Short Term Provisions	46.97	51.47
		<b>2,385.44</b>	<b>1,666.66</b>
	<b>TOTAL</b>	<b>4,590.43</b>	<b>3,716.74</b>
<b>II.</b>	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	<b>Property Plant &amp; Equipments</b>		
<b>1</b>	<b>Fixed assets</b>		
	(i) Tangible Assets	990.72	978.36
	(ii) Capital Work in Progress	-	-
	(iii) Intangible Assets	8.17	9.16
	(iv) Intangible Assets Under Development	2.30	1.80
	Goodwill	32.70	32.70
	Non Current Investments	188.04	188.04
	Long Term Loans & Advances	0.00	-
	Deferred Tax Assets	14.24	7.21
	Other Non Current Assets	35.53	36.14
		<b>1,271.69</b>	<b>1,253.41</b>
<b>2</b>	<b>Current assets</b>		
	Current Investments	-	-
	Inventories	1188.42	915.52
	Trade Receivables	2052.88	1,343.81
	Cash and cash equivalents	25.01	50.56
	Short Term Loans & Advances	15.77	110.94
	Other Current Assets	36.66	42.50
		<b>3,318.74</b>	<b>2,463.33</b>
	<b>TOTAL</b>	<b>4,590.43</b>	<b>3,716.74</b>

For Walpar Nutritions Limited

**Kalpesh P Ladhawala**  
**Managing Director**  
**DIN : 02849232**

Place : Gandhinagar  
 Date : November 12, 2024

**WALPAR NUTRITIONS LIMITED**

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Cash Flows for the year ended on September 30, 2024

(Amount in Lakhs)

Particulars	For The Period Ended on	For The Year Ended on
	30.09.2024	30.09.2023
<b>Cash flows from operating activities</b>		
<b>Profit before taxation</b>	<b>180.79</b>	<b>79.95</b>
<b>Adjustments for:</b>		
Depreciation	87.91	92.41
Investment income	(0.02)	(0.14)
Prior Period Items/Non Cash Items	8.03	0.01
Finance Cost	25.70	32.79
<b>Working capital changes:</b>		
(Increase) / Decrease in Trade Receivables	(709.07)	(580.62)
(Increase) / Decrease in Short Term Loans & Advances	95.17	102.59
(Increase) / Decrease in Other Current Assets	5.84	52.35
(Increase) / Decrease in Inventories	(272.90)	(169.51)
Increase / (Decrease) in Trade Payables	784.41	783.00
Increase / (Decrease) in Other Current Liabilities	(80.43)	(48.19)
Cash generated from operations	<b>125.43</b>	<b>344.64</b>
Payment/Adjustmen on Account of Tax Expenses	(51.47)	(17.65)
<b>Net cash from operating activities</b>	<b>73.96</b>	<b>326.99</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(99.78)	(76.21)
Investment Income	0.02	0.14
(Increase)/Decrease in Non Current Investments	0.00	(186.55)
(Increase)/Decrease in Other Non Current Assets	0.61	6.59
<b>Net cash used in investing activities</b>	<b>(99.14)</b>	<b>(256.03)</b>
<b>Cash flows from financing activities</b>		
Proceeds/ (Repayment) of Short term Borrowings	19.30	-3.24
Proceeds/ (Repayment) of Long term Borrowings	6.03	-159.97
Proceeds from Share Capital	-	15.40
Proceeds from Securities Premium	-	75.05
Payment of Finance cost	(25.70)	(32.79)
<b>Net cash used in financing activities</b>	<b>(0.37)</b>	<b>(105.55)</b>
<b>Net increase in cash and cash equivalents</b>	<b>(25.55)</b>	<b>(34.59)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>50.56</b>	<b>53.81</b>
<b>Cash and cash equivalents at end of period</b>	<b>25.01</b>	<b>19.22</b>

For Walpar Nutritions Limited

Kalpesh P Ladhawala  
 Managing Director  
 DIN : 02849232

Place : Gandhinagar  
 Date : November 12, 2024





# **A Y & COMPANY**

505, Fifth Floor, ARG Corporate Park  
Gopal Bari, Ajmer Road, Jaipur (Raj.)  
TEL NO. - +91-8003056441  
Email: info@aycompany.co.in

## **Limited Review Report on the Half Year Ended Un-audited Consolidated Financial Results of company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

### **Review Report**

**To**

**The Board of Directors  
Walpar Nutritions Limited**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Walpar Nutritions Limited ("the Parent"), which includes its subsidiaries (the Parent and its subsidiary together referred to as 'the Group') for half year ended on September 30, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.



## A Y & COMPANY

505, Fifth Floor, ARG Corporate Park  
Gopal Bari, Ajmer Road, Jaipur (Raj.)  
TEL NO. - +91-8003056441  
Email: info@aycompany.co.in

4. The Statement includes the results of its subsidiaries:
  1. Walpar Wellness Private Limited (A Company incorporated under Companies Act, 2013).
  2. Walpar Nutri Science Private Limited (A Company incorporated under Companies Act, 2013).
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the auditor's review reports of subsidiary companies referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information of subsidiary companies whose interim financial results reflects total revenues for the half year ended on September 30, 2024, are Rs. 1282.70 Lakhs, total net profit (loss) after tax for the half year ended on September 30, 2024 is Rs. 29.27 Lakhs as considered in unaudited financial results.

**For A Y & Company**  
**Chartered Accountants**  
**FRN: 020829C**



**Arpit Gupta**  
**Partner**  
**M. No. 421544**  
**UDIN – 24421544BKFPPW5307**  
**Place: Jaipur**  
**Date: 12.11.2024**